利伐沙班与达比加群酯在老年非瓣膜病慢性房颤患者长期抗凝治疗中的效果对比

Comparison of effects of rivaroxaban and dabigatran in long-term anticoagulant therapy for elderly patients with non-valvular chronic atrial fibrillation

中文关键词: 老年  非瓣膜病  慢性房颤  利伐沙班  达比加群酯  抗凝治疗

英文关键词: elderly  non-valvular disease  chronic atrial fibrillation  rivaroxaban  dabigatran  anticoagulation therapy

中文摘要:

      目的 探讨利伐沙班与达比加群酯在老年非瓣膜病慢性房颤(NVAF)患者长期抗凝治疗中的效果.方法 选取2023年1月—2023年10月华东医院收治的82例NVAF患者,随机分为利伐沙班组(Riva组)和达比加群酯组(Dabi组),每组各41例.比较2组患者的凝血功能、肝肾功能、栓塞事件、出血事件以及不良反应的情况.结果 2组的凝血酶时间(TT)、国际标准化比值(INR),治疗前后及组间差异无统计学意义(P＞0.05);活化部分凝血酶时间(APTT)在治疗过程中出现显著变化,治疗3个月和12个月时Dabi组高于Riva组(P＜0.05).2组肝肾功能、栓塞事件、出血事件及不良反应发生率差异无统计学意义(P＞0.05).结论 利伐沙班与达比加群酯在老年NVAF患者中均具有良好的抗凝效果和安全性.

英文摘要:

      Objective To investigate the efficacy of rivaroxaban and dabigatran in long-term anticoagulation therapy for elderly patients with non-valvular chronic atrial fibrillation(NVAF).Methods 82 NVAF patients admitted to Huadong Hospi-tal from January to October 2023 were selected and randomly divided into rivaroxaban group(Riva group)and dabigatran group(Dabi group),with 41 patients in each group.The coagulation function,liver and kidney function,thromboembolic events,bleeding events,and incidence of adverse reactions were compared between the two groups.Results There were no statistically significant differences in thrombin time(TT)and international normalized ratio(INR)between the two groups be-fore and after treatment(P＞0.05).The activated partial thrombin time(APTT)changed significantly during the treatment.At 3 months and 12 months of treatment,the APTT level of the Dabi group was higher than that of the Riva group(P＜0.05).There were no statistically significant differences in liver and kidney function,and the incidence of thromboembolic events,bleeding events and adverse reaction between the two groups(P＞0.05).Conclusion Both rivaroxaban and dabigatran dem-onstrate good anticoagulation efficacy and safety in elderly NVAF patients.